Yesterday, Oxford University launched human clinical trials for a new Ebola vaccine powered by 4,000 doses made in Pune. This breakthrough highlights India's rise from a basic generic drug manufacturer to a co-developer of global vaccines.
4,000
Bundibugyo Ebola Trial Doses
Approved Vaccine Doses: 0→4,000
⏳ Time Machine
How today’s news fits into the bigger picture
10 years ago
During the massive 2014-2016 West African Ebola crisis, the world realized it had zero fast-response vaccine platforms ready for deployment.
Last year
By mid-2025, researchers completed preclinical animal testing on the Bundibugyo candidate, showing highly promising immune responses.
Last month
Regulators cleared the manufacturing protocols at the Serum Institute's Pune facility for experimental production in June 2026.
Yesterday
Oxford and the Serum Institute finalized the logistical details to ship the first clinical trial vaccine vials to UK clinics.
Today
Oxford began human trials of the Bundibugyo Ebola vaccine, powered by 4,000 doses made in India.
What happens next?
Efficacy trials are expected to expand to sub-Saharan Africa by early 2027 if safety trials conclude successfully.
Yesterday, Oxford University launched the world's first human clinical trials for a new vaccine targeting the deadly Bundibugyo strain of the Ebola virus. This global medical breakthrough is powered by Pune-based Serum Institute of India, which manufactured and supplied 4,000 trial doses. While Ebola remains a terrifying threat in sub-Saharan Africa, current vaccines only protect against the Zaire strain, leaving millions vulnerable to other variants. The Indian pharma giant’s rapid scale-up of these experimental doses underscores India's evolving role from a cheap generic manufacturer to a critical co-developer of cutting-edge global vaccines. If successful, this trial will not only save lives across Africa but also cement India’s position as the indispensable pharmacy of the developing world.
💭 If you're wondering…
Ebola has multiple distinct viral strains. Existing vaccines only protect against the Zaire strain, leaving people completely exposed to the Bundibugyo strain.
Did this story help?
Official sources
Knowledge Chain — tap a concept